Browse by Audience
Skip to content
Papers of the Week
The paradigm shift of long-term treatments in migraine prevention.
Authors
Abstract
Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor are a key achievement in the field of migraine prevention, being the first migraine-specific preventatives. Several characteristics distinguish monoclonal antibodies targeting the CGRP pathway from the previously available drug classes for migraine prevention, including their specificity, their monthly or quarterly subcutaneous administration, and their rapid onset of action.